Tenax Therapeutics Inc. (NASDAQ: TENX)
$3.37
+0.0050 ( +0.15% ) 11.1K
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Market Data
Open
$3.37
Previous close
$3.36
Volume
11.1K
Market cap
$6.64M
Day range
$3.21 - $3.42
52 week range
$2.77 - $61.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 17 | Jun 13, 2024 |
4 | Insider transactions | 1 | May 21, 2024 |
4 | Insider transactions | 1 | May 21, 2024 |
8-k | 8K-related | 17 | May 14, 2024 |
10-q | Quarterly Reports | 52 | May 14, 2024 |
ars | Annual reports | 86 | Apr 26, 2024 |
def | Proxies and info statements | 7 | Apr 26, 2024 |
8-k | 8K-related | 17 | Mar 28, 2024 |
10-k | Annual reports | 74 | Mar 28, 2024 |
8-k | 8K-related | 16 | Feb 23, 2024 |